With more than 70 members the Sealy Institute for Vaccine Sciences (SIVS) incorporates the expertise of more than 100 cutting-edge research programs. The faculty and staff of the SIVS strive to generate, perfect, and promote the most effective and safest disease prevention strategies. In this effort, the Institute carries on the proud tradition of medical research and discovery that has been a hallmark of the University of Texas Medical Branch (UTMB) since its inception.
See full profile
The SIVS combines the expertise of basic scientists in many areas, including virologists, bacteriologists, parasitologists, materials scientists and immunologists, and physician-scientists who undertake clinical research and regulatory scientists with experience necessary to prepare a candidate vaccine for progression into the testing and evaluation pipeline.
As one of the most comprehensive university-based vaccine development centers in the US, the SIVS participates in four out of the five components (excluding manufacturing) of the vaccine development pathway:
- Basic & Discovery Research
- Vaccines for infectious diseases, including chronic diseases
- Biothreat agents, BSL2-BSL4
- Pre/Nonclinical Development
- Animal models of infectious diseases
- Regulated studies and quality systems
- Clinical Research and Trials
- Phase I-IV vaccine clinical trials
- Federal and Pharma studies
- Policy and vaccine acceptance research
- Public and healthcare provider education
Visit website: www.utmb.edu/sivs